Stack · Skin / cosmetic
GHK-Cu + BPC-157 + TB-500 (“GLOW”)
Sold under the community name “GLOW” as a skin-and-repair combination: a copper peptide associated with cosmetic collagen research, plus two compounds with preclinical wound-healing literature. The rationale is mechanistic storytelling, not a studied protocol, and vendor constituent lists for products using this name are not consistent.
Compounds
- GHK-Cu
Copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine
No FDA-approved product
- BPC-157
Synthetic 15-residue peptide corresponding to a partial sequence of human gastric juice protein BPC
No FDA-approved product
- TB-500
Synthetic acetylated heptapeptide corresponding to the actin-binding region of thymosin beta-4 (residues 17–23)
No FDA-approved product
Why people combine them
Sold under the community name “GLOW” as a skin-and-repair combination: a copper peptide associated with cosmetic collagen research, plus two compounds with preclinical wound-healing literature. The rationale is mechanistic storytelling, not a studied protocol, and vendor constituent lists for products using this name are not consistent.
Therapept evaluates multi-peptide combinations like GHK-Cu + BPC-157 + TB-500 (“GLOW”) by analyzing whether the biological pathways operate independently, competitively, or synergistically, comparing preclinical hypotheses against documented human trials.
Evidence for the combination
This pairing rests entirely on community practice. No published study and no registered trial of the combination is indexed by Therapept.
Evidence for each component
- GHK-Cu — Copper tripeptide with cosmetic topical use and laboratory extracellular-matrix research; no approved drug product and no large human hair or skin trial indexed.
- BPC-157 — Predominantly rodent and cell data plus one small retrospective human case series; no completed randomised Phase 3 trial indexed.
- TB-500 — The LKKTETQ fragment; human wound-healing literature concerns the full-length parent protein, not this fragment.
Commonly reported dosing and protocols
Displayed source by source. Therapept does not compose these into a recommended protocol.
Potential overlap and concerns
- No published study evaluates this three-component combination. There is no combination-specific human safety or efficacy evidence.
- BPC-157 and TB-500 are prohibited in sport under the WADA 2026 Prohibited List; GHK-Cu is not listed.
- The name does not define the contents. Two products sold as “GLOW” may contain different compounds, quantities or forms, and a certificate of analysis is the only way to know what a lot contains.
- Mixing compounds in one vial creates compatibility, aggregation and characterisation questions that no cited source has answered for this combination.
What is known
- Each component has a separate evidence file with its own limits.
- Copper peptides have a cosmetic topical history; the other two do not have approved products.
What is speculative
- Every claim that these three compounds work better together than separately.
- Any suggested ratio, schedule or injection protocol.
- The idea that a cosmetic-ingredient designation supports injectable use of GHK-Cu.
Sources
Last reviewed 17 September 2026 · Compiled by Therapept Editorial · How these records are built